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Long Ngo, and Lori Pbert
Abstract
Background. Most people with multiple sclerosis (MS) want to be involved in medical decision making about disease-
modifying therapies (DMTs), but new approaches are needed to overcome barriers to participation. Objectives. We
sought to develop a shared decision-making (SDM) tool for MS DMTs, evaluate patient and provider responses to the
tool, and address challenges encountered during development to guide a future trial. Methods. We created a patient-
centered design process informed by image theory to develop the MS-SUPPORT SDM tool. Development included
semistructured interviews and alpha and beta testing with MS patients and providers. Beta testing assessed dissemination
and clinical integration strategies, decision-making processes, communication, and adherence. Patients evaluated the tool
before and after a clinic visit. Results. MS-SUPPORT combines self-assessment with tailored feedback to help patients
identify their treatment goals and preferences, correct misperceptions, frame decisions, and promote adherence. MS-
SUPPORT generates a personal summary of their responses that patients can share with their provider to facilitate com-
munication. Alpha testing (14 patients) identified areas needing improvement, resulting in reorganization and shortening
of the tool. MS-SUPPORT was highly rated in beta testing (15 patients, 4 providers) on patient-provider communica-
tion, patient preparation, adherence, and other endpoints. Dissemination through both patient and provider networks
appeared feasible. All patient testers wanted to share the summary report with their provider, but only 60% did.
Limitations. Small sample size, no comparison group. Conclusions. The development process resulted in a patient-
centered SDM tool for MS that may facilitate patient involvement in decision making, help providers understand their
patients’ preferences, and improve adherence, though further testing is needed. Beta testing in real-world conditions was
critical to prepare the tool for future testing and inform the design of future studies.
Keywords
shared decision making, communication, multiple sclerosis, adherence, patient preferences, values clarification, image
theory, chronic disease
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Introduction
Multiple sclerosis (MS) is a chronic, progressive disease of
the central nervous system with unpredictable neurologic
manifestations that can affect many dimensions of health
(e.g., physical, emotional, social).1 Disease-modifying
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use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and
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therapies (DMTs) can slow disease activity, decrease
relapse rates, and reduce the accumulation of disability.2,3
MS patients face several difficult decision points during the
course of their illness: for example, whether to take steroids
for an acute relapse, whether to initiate DMT early in the
disease, which DMT to take, and whether to change or dis-
continue a DMT. DMT options have expanded in recent
years to include a range of mechanisms of action, routes of
administration (self-injection, infusion, oral), efficacy,
adverse effects, and costs.4 The complexity and uncertain-
ties in the evidence surrounding DMT decisions make
them appropriate for shared decision making (SDM),5
where treatment decisions are based on the best available
evidence and the patients’ health goals, preferences, and
values.6
Clinical guidelines for MS2,7 recommend incorporat-
ing patient preferences for treatment safety, route of
administration, lifestyle, cost, efficacy, adverse effects,
and tolerability into DMT decisions. However, doing so
can be difficult. Patients often are unclear about their
preferences when faced with a new or complex situation
and may have difficulty applying their values to health
decisions.8,9 Semantic issues arise when terms used to
describe preferences (e.g., tolerability, lifestyle, safety)
confer different meanings to providers and patients.10
Difficult trade-offs among personal values (e.g., efficacy
versus risk) can induce negative emotions that may lead
people to avoid or delay decision making or to choose
the default option.11,12 Physicians often make assump-
tions about what matters to patients, but those assump-
tions are often incorrect.13–16 A variety of approaches
have been developed to help patients clarify their values
with respect to a treatment decision,17,18 but these
approaches typically rely on preference items selected by
the developer or physicians, which may not be relevant
to patients.19
Patients need trusted, up-to-date information to
engage in SDM, but the amount and essential elements
of that information are undefined.20 Too much informa-
tion can interfere with decision making and result in peo-
ple focusing on only part of the information, screening
out information or options based on initial impressions,
settling on the first option that appears satisfactory, or
using contextual cues to make a choice.21 SDM provides
a framework for identifying the types of information
needed to facilitate decision making22,23 (e.g., list all
options, describe positive and negative features, describe
natural history without treatment).19 However, SDM
offers little guidance on how to manage a wide range of
options and features or how to present information to
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patients to support decision making.24 In contrast, image
theory25 describes how people make complicated value-
laden decisions involving multiple options. Image theory
depicts decision making as a two-step process. The first
step involves focusing on the negative attributes of the
options to screen-out options that are incompatible with
one’s values and goals. The next step involves examining
the pros and cons of each remaining values-compatible
option to choose the best one.26 Validated in multiple set-
tings27 and endorsed for SDM,28 image theory informed
the design of the SDM tool.
Adherence to DMT is critical to achieve full treatment
benefits,29,30 yet adherence is low, ranging from 41% to
95%.31–34 SDM may improve adherence, but the evi-
dence is inconclusive.35 A recent review concluded that
SDM can improve adherence to DMTs,36 based in part
on a study showing that patients who did not feel well-
informed by their neurologist were more likely to be non-
adherent.37 SDM may improve adherence to DMTs by
helping MS patients and providers choose a DMT that is
more consistent with the patient’s treatment goals, pre-
ferences, and lifestyles.
The objectives of this study are to 1) describe the
development of a patient-centered SDM tool that also
targets adherence; 2) describe patient and provider
responses to the tool; and 3) discuss challenges in devel-
opment and implementation.
Methods
Overview
This study is part of a larger mixed-methods study (the
MS Decisions Study) to develop and evaluate web-based
SDM tools for MS patients. The patient-centered design
process was guided by formative work, relevant theory
(Table 1),28 and SDM guidance.23 We previously devel-
oped10 and validated38 a preference tool to assess patient
treatment goals for MS and patient preferences for the
attributes of DMTs. That preference tool served as the
nucleus for MS-SUPPORT.
All patient-facing content was co-written and iteratively
revised by people with MS and reviewed by experienced
providers for scientific accuracy. As part of our develop-
ment process, people with MS iteratively assessed the
tool’s usability (alpha testing); patients and providers itera-
tively assessed the tool within the context of a clinical MS
appointment during beta testing. This study was approved
by the New England Independent Review Board. All par-
ticipants provided written (online) informed consent.
Previous Work Identifying Patients’
Goals and Preferences
Cognitive mapping informed the design of the values clar-
ification modules, using previously published methods.10
In brief, we used the nominal group technique to identify
and prioritize patient treatment goals, preferences for
DMT attributes, and factors driving a change in treat-
ment. We used card sorting coupled with hierarchical
cluster analysis and multidimensional scaling39–42 to cre-
ate a cognitive map that organized preference items into
meaningful clusters. These clusters comprised the lists of
goals and preferences included in the values clarification
modules and were independently validated.38
The SDM Tool: MS-SUPPORT
MS-SUPPORT is an interactive, online decision aid
designed to encourage patient-provider collaboration
and promote treatment adherence. The tool emphasizes
patient engagement, patient-provider communication,
Table 1 Theory-Based Features of MS-SUPPORT
Theory-Based Recommendation Feature in Tool
Optimize representation. All preference items and content were derived from and
organized by experienced patients.
Include all potentially appropriate options and their attributes. All relevant attributes of all options are shown to patients.
Suspend selection of an initially favored options (pre-selection). Start by focusing only on attributes, not options. Introduce
options afterwards.
Remind decision maker of the array of values. Include activities that require attention to the complete array
of values (broad and narrow)—choosing, ranking, and
rating.
Facilitate weighting of attributes. Force selection of top 3 in importance, then rank, then rate
each subcomponent.
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SDM, healthy lifestyles, and treatment adherence.
Design features include accessibility on multiple plat-
forms, scalability, encryption, HIPAA compliance, and
various options for dissemination and clinical integra-
tion. Content can be rapidly updated online. The tool
employs principles of effective communication43,44
including positive framing, side-by-side comparisons,
graphics, plain language, highlighting important infor-
mation, and a user-driven path. The average reading
level is grade 6.9.45 The tool was created using custo-
mized Qualtrics software.
MS-SUPPORT guides users through a series of struc-
tured, interactive modules (Figure 1). It provides perso-
nalized feedback based on the patient’s stated goals,
preferences, needs, situation, adherence, and health
behaviors, generating a concise summary that is emailed
to the patient to share with their provider (Figure 2).
Sharing can be accomplished by printing or emailing the
summary, copying it into the electronic patient portal, or
using a mobile device. MS-SUPPORT also generates
and emails a comprehensive personal report to the
patient that includes information on the topics of interest
selected by the patient. Patients do not have to complete
all the modules at once; they can log back in later to
complete the tool.
General Tool Design and Rationale. The introductory
section of the tool is designed to set the emotional tone,
build trust, and promote engagement. It assesses the
patient’s role preference in the decision-making process
(using the Control Preferences Scale)46 and provides tai-
lored feedback about the importance of engagement and
communicating their preferences with their provider.
Values Clarification Exercises. Multitiered values clarifi-
cation exercises help the user identify and prioritize their
MS treatment goals and preferences for DMT attributes
by asking the user to select the most important broad
goals (or attributes) from a list. Next, the user rates the
importance of conceptually related but more specific
items within those broad goals (or attributes). Last, addi-
tional preference items can be added by the user. Once
this exercise is completed, MS-SUPPORT generates a
succinct summary of the patient’s goals and preferences
and explains how to use goals and preferences to guide
decisions. Other preference modules follow a similar
design. Values clarification exercises precede discussion
of specific DMT options in order to minimize the prema-
ture elimination of options that might seem incompatible
with one’s values (keeping with image theory).
Defining the Scope and Key Content Messages. During
formative work, we became aware of information gaps
and misperceptions about MS and DMT that could
interfere with informed decision making. To more sys-
tematically identify common patient misconceptions and
information gaps about DMTs, we convened a very
small convenience sample of patients and providers. The
sample included five patient advisers who were peer-to-
peer educators (e.g., moderating MS blogs and/or sup-
port groups) and five experienced MS providers (three
medical doctors, one physician assistant, one registered
nurse) from different parts of the United States. Advisers
independently answered the question, ‘‘In your opinion,
what do you think are the most important mispercep-
tions and information gaps that interfere with good
decision-making about DMTs?’’ After responding to the
question, each respondent was shown responses from
previous respondents to stimulate new ideas. They were
also asked for suggestions for correcting those gaps and
misperceptions (Table 2). Responses guided the content
and scope of the tool. For example, because patients did
not clearly distinguish between symptom management
and slowing disease progression, the tool addressed
symptoms as well as DMTs. Because of the many mis-
conceptions regarding lifestyle and DMTs, which could
affect symptoms and disease progression, a lifestyle mod-
ule was included.
Presenting Decisions. DMT decisions were classified as
either starting, stopping, or switching treatment, depend-
ing on current DMT use. Options were presented to bal-
ance the general risks, benefits and inconveniences of
DMTs as a class against the risks, benefits and inconve-
niences of not taking DMTs. The attributes of specific
DMTs were subsequently compared. Different graphic
representations, including balance scales and flow charts
(Figure 3), aided comprehension.
Comparing Options. A simplified table compares the
effectiveness and risks of specific DMTs. Using an itera-
tive design process, we initially developed a table com-
paring each treatment’s relative risk estimate for each
benefit and risk, in accordance with SDM guidance.22,23
Despite numerous revisions, we abandoned this approach
due to persistent misinterpretation by the testers. Indeed,
the scientific evidence does not support head-to-head
comparisons among DMTs at this time. Cross-DMT
comparisons are confounded by differences in each trial’s
comparison group. Providing general information about
a treatment’s effectiveness on different outcomes by using
4 MDM Policy & Practice 00(0)
Figure 1 Content diagram of MS-SUPPORT. *Summary individualized based on patient responses. Summary and content
e-mailed to patient.
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Summary of your responses and preferences    4/11/2018  
RRMS since 2007 
 Symptoms began: 2004 
Can walk Couple miles without stopping 
Assistive devices used: None 
0 falls last month
MS symptoms: 0 means not at all bothersome, 10 means most bothersome 
  Pain: 1 
  Fatigue: 4
  Thinking: 6 
  Weakness: 6 
  Numbness/tingling: 9  
  Spasticity: 1   
  Arms: 1     
  Legs: 1     
  Vision: 1     
  Bladder: 5
  Bowel: 1 
  Balance: 5 
  Heat sensitivity: 1 
  Sex: 1    
Not depressed// No anxiety 
Preferred role: Make the final selection myself after seriously considering my doctor's opinion 
Goals for MS treatment      
  #1: Avoid flare-ups or progression 
  #2: Finding the best medication 
  #3: Disability concerns 
Specific goals: keep the brain healthy (avoid brain atrophy), maintain clear thinking, better balance 
(for example, avoid falling), avoid or slow progression of MS, avoid flare-ups  
Important DMT features
 #1: Effectiveness 
 #2: Confidence in the treatment 
 #3: Serious side-effects 
 #4: Brain health 
 #5: Managing symptoms 
Specifics: ability to prevent underlying disease progression, effectiveness in preventing further 
disability, feeling better while on treatment, effectiveness in preventing new or enlarging MRI lesions, my 
other health conditions.  
Current DMT: Tecfidera® (dimethyl fumarate) 
Past DMT: Copaxone® (glatiramer acetate), Rebif® (interferon b-1a), Tysabri® (natalizumab), Rituxan®
(rituximab)  
  Why stopped: Copaxone: It was not stopping my relapses or progression// Rebif: It was not stopping 
my relapses or progression// Tysabri: JC Virus Positive// Rituxan: I kept getting sick //  
Interested in changing DMT: Yes because I am getting continuous infections and feel like it is time for a 
change 
Adherence: 0 missed DMT doses.  
 Challenges taking DMTs as prescribed: When your routine is messed up. 
Able to give injections: Yes, I can do it myself   
Lifestyle: No tobacco use, Up to one drink a day, Perceived weight: Somewhat overweight, Not enough 
regular exercise: exercises only 3 times/week. Interested in changing now: lose weight; Interested in 
changing later: exercise more
Questions for provider: What new medication can I change to that will work differently from Tecfidera 
Figure 2 Sample overall summary generated by MS-SUPPORT.
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Figure 3 Screen shots from MS-SUPPORT. Examples of presenting decisions in MS-SUPPORT.
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a check mark system within the comparison table (Figure
4) proved useful and acceptable to patient and providers.
Encouraging Adherence. We developed an adherence
module that explains the benefits of adhering to DMTs
and addresses individual barriers to adherence. Reasons
for nonadherence and strategies for remediation were
compiled based on a targeted literature review31–33,47–50
and formative work (e.g., misperceptions about DMTs).
This compilation was transformed into self-assessment
instruments, each iteratively revised by patients and pro-
viders. These instruments assessed the number of recently
missed DMT doses, reasons for past nonadherence, and
anticipated barriers to future adherence. Tailored feed-
back addressed problem areas, provided practical tips
and resources, and summarized patient responses.
Alpha and Beta Testing
Participants. Participants included non-pregnant, English-
speaking patients between the ages of 21 and 75 who
self-identified as having MS, were not enrolled in a clin-
ical trial of an MS medication, and had access to the
Internet. Beta testing was further limited to patients
with an upcoming appointment with their MS provider
within 12 weeks.
We initiated an online participant panel for this study
in January 2015 composed of participants who were
referred to the study (opt-in) through multiple methods,
including referrals by participating providers, patient
advisers, support groups, and private Facebook groups.
All referrals were facilitated by patient advisers or parti-
cipating providers to ensure that only subjects with a
diagnosis of MS were included. Alpha-testers were identi-
fied through the patient panel; beta-testers were referred
from patients or participating providers.
Data Collection. Potential participants were emailed
invitations to review and evaluate MS-SUPPORT
between October 1, 2017, and May 1, 2018. Invitations
included a web link to a secure website that directed the
participant though the eligibility screener, informed con-
sent document, and baseline questionnaire. Questions
assessed sociodemographics, current and previous DMT
use, adherence, and self-reported knowledge about MS
and treatment options. For beta-testers, we also asked
for the date of their upcoming provider appointment
and provider name. Eligible participants were emailed a
unique, nontransferable link to the MS-SUPPORT tool
that included evaluation questions. Beta testing subjects
were emailed a second evaluation on the day of their
scheduled provider appointment. Participants received
Figure 4 Comparing DMT options.
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an incentive payment ($25 online gift card) after each
completed evaluation.
Assessments
Alpha testing included online evaluation and structured
video-conference interviews. Assessments addressed
overall evaluation (‘‘I would recommend it to others with
MS’’), usability (‘‘It was easy to use,’’ ‘‘It was easy to
read,’’ ‘‘It was well organized,’’ ‘‘It kept my interest,’’ ‘‘It
contained the right amount of information’’), trust in the
information (‘‘I trusted the information provided,’’ ‘‘It
presented unbiased information’’),51 patient-provider
communication (‘‘It addressed topics that are important
in communicating with my doctor’’), values clarification
(‘‘It helped me understand the things that matter most to
me about my MS), knowledge (‘‘It helped me understand
my treatment options’’), adherence (‘‘I helped me under-
stand the importance of taking DMTs as prescribed,’’ ‘‘It
makes me more likely to take my medications as pre-
scribed’’), and suggestions for improvement.
Beta testing additionally evaluated the use of the tool
in the context of a clinical visit with an MS provider.
Beta-testing questions also addressed preparedness for
the clinical visit (e.g., ‘‘It will help me make the most of
my next MS doctor’s visit’’), decision making (‘‘It pre-
pared me to make better decisions about MS’’), commu-
nication (‘‘It will help me talk to my doctor about what
matters most to me’’), stage of decision making,52 pre-
paration (It will help me prepare for my next MS
appointment’’), and role preferences (‘‘It helped me think
about how involved I want to be in MS decisions’’ and
the validated role preference scale46). Survey response
options used a 5-point Likert-type scale (‘‘strongly dis-
agree,’’ ‘‘somewhat disagree,’’ ‘‘neither agree nor dis-
agree,’’ ‘‘somewhat agree,’’ ‘‘strongly agree’’). After their
provider appointment, we assessed SDM-relevant items
from the Consumer Assessment of Healthcare Providers
and Systems (CAHPS) Clinician and Group Survey53 for
Merit-based Incentive Payment System and their experi-
ence sharing their summary with their provider.
Questions addressed their provider’s interest in reviewing
the summary, whether the summary helped them talk to
their provider about their preferences, challenges encoun-
tered, and whether MS-SUPPORT affected the quality of
the visit, decision making, and motivation to make life-
style changes. Likert response categories were ‘‘not at
all,’’ ‘‘very little,’’ ‘‘somewhat,’’ ‘‘a lot,’’ or ‘‘a great deal.’’
Participating providers were emailed a brief online
survey just after interacting with a patient participant.
An incentive payment of $50 was offered for each
completed provider survey. We asked providers ques-
tions about patient-provider communication, the useful-
ness of the patient summary, and the patient’s
preparation for the visit.
Results
Alpha testing included 14 patients with MS, of whom 11
completed the online evaluation and 9 participated in a
video-conference interview (Appendix 1). A separate
sample of 40 patients were invited to participate in beta
testing (Appendix 1), of whom 15 completed the screen-
ing process and evaluations (Appendix 2). Those who did
not complete the screening process were slightly younger
and more likely to be white, male, and less educated than
participants.
Alpha Testing
We iteratively revised the tool’s content, design, and tai-
loring algorithms during alpha testing until all identified
problems were addressed and satisfactory usability rat-
ings were obtained. This process resulted in shortening
passages, removing inessential or repetitive elements, cor-
recting programming errors, introducing skip patterns,
tiering information, offering less important information
as optional drill-downs, and emailing information of
interest to the user upon completion. Findings are shown
in Appendix 3. Because MS-SUPPORT underwent sub-
stantial revisions during alpha testing, we focus on beta
testing finding.
Beta Testing
It took patients an average of 62 minutes (adjusting for
outliers; range 18-496) to complete the tool. Twenty-five
percent completed the tool within 36 minutes, including
the evaluation module and any breaks the patient may
have taken. All15 patient beta-testers wanted to share
their summary with their provider, but only 8 did (7
brought a printed copy [3 out of 8 patients requested that
the printout be mailed to them due to challenges printing
it themselves.], 1 used their smartphone; 2 reported ver-
balizing the summary to their provider after forgetting to
bring the report with them). Many logistical problems
reported by patients were due to a single programming
error that prevented patients from sharing their summary
with their provider and which was corrected during beta
testing. All who shared their summary reported that they
(not their provider) initiated discussion about the sum-
mary. All patients agreed or strongly agreed that the
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report was easy to share, that they felt comfortable shar-
ing it, and that their provider seemed interested in review-
ing their report during the visit. Most of their providers
asked them questions about the report. Six of seven
patients agreed or strongly agreed that ‘‘the summary
report helped me talk to my provider about my prefer-
ences’’ (the remainder neither agreed nor disagreed).
Patient evaluations after viewing MS-SUPPORT
(before the clinic visit) were favorable (Figure 5). Higher
ratings were reported on topics that were applicable to
everyone (e.g., trust in the information, preparing for
appointments, communication) as compared to topics
that were more relevant to those with specific issues (e.g.,
severe symptoms) or behaviors (e.g., nonadherence).
‘‘Not applicable’’ was not a response option and all
participants received the same evaluation questions.
MS-SUPPORT improved 6 of 15 participants’ stage of
decision making (Figure 6).
Patient evaluations after the clinic visit suggested that
the tool helped most patients with decision making, com-
munication, and preparation (Appendix 4). Patients who
shared their summary (compared to those who did not)
reported higher evaluations of their providers and higher
CAHPS metrics (Appendix 5).
Provider Evaluations
Fourteen patient participants were associated with 12
different providers. Four of these providers (all neurolo-
gists) completed six evaluations of MS-SUPPORT (one
provider saw three participating patients). Four of these
evaluations reflected visits where the patient shared their
personal summary. Providers reported that it took an
average of 5.25 minutes (range 1-10 minutes) to review
the summary. All providers would recommend MS-
SUPPORT to a colleague. Most reported that MS-
Figure 5 Patient evaluation of MS-SUPPORT before provider appointment (n= 15).
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SUPPORT improved the quality of care provided, the
efficiency of the visit, and their knowledge of and inter-
action with the patient (Appendix 6). Evaluations were
more positive for the four encounters in which patients
shared versus did not share their personal summary.
Discussion
The patient-centered design process described succeeded
in guiding the design and delivery of a feasible and poten-
tially effective SDM tool for MS. Having patients with
MS guide all stages of development added substantial
complexity to the design process but increased the tool’s
patient-centeredness. The development process adhered
to SDM guidelines and included recommended alpha
testing with patients and beta testing in ‘‘real-life’’ condi-
tions.23 Additional design processes and theoretical fra-
meworks were needed to address challenges that were not
readily addressed by SDM guidelines. Image theory was
instrumental in structuring information. Despite the large
amount of information and options included in the tool,
all testers felt MS-SUPPORT contained the right amount
of information. The pilot alpha and beta testing included
in the development process was instrumental in devel-
oping the intervention and guiding subject recruitment,
intervention delivery, and sample size calculations for
future studies and dissemination. Pilot testing that
encompasses recruitment and delivery strategies has
been called for in other areas54 and is especially valu-
able for SDM tools, where dissemination challenges
persist.
Disseminating the tool to patients through patient-
referral networks was feasible, required no effort by pro-
viders, and helped deliver the tool to patients who lack
MS specialty care. However, delivering MS-SUPPORT
to patients just in time to prepare for a clinical appoint-
ment was challenging. Providing the tool too early
resulted in patients forgetting to bring their summary
with them to the appointment while providing it too late
did not give patients enough time to review MS-
SUPPORT. Timely reminders might help overcome
these challenges.
An unexpected finding was that all patients wanted to
share their personal summary with their provider and all
who did reported it was easy to share. However, imple-
mentation challenges were encountered. Despite offering
Figure 6 Each line represents one patient participant’s stage of decision making before (blue bubbles) and after (green bubbles)
viewing MS-SUPPORT.
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several options for sharing the report, most patients
relied on manual printing instead of the patient portal,
even though the latter facilitated delivery via the elec-
tronic health records (EHRs). Participants lacked famil-
iarity with utilizing patient portals in this manner
(portals are typically used to view laboratory results or
schedule appointments). Sending reminders before the
HCP visit and helping patients access and use their
patient portal should help. Embedding the tool directly
into an EHR should obviate many logistical problems
encountered, making it possible to trigger access to the
tool prior to upcoming appointments and incorporate
the summary page into the patient’s EHR, but was
beyond the scope of this project.
We designed MS-SUPPORT to improve adherence
by targeting factors that contribute to nonadherence.
These factors include poor patient-provider communica-
tion, patient attitudes and beliefs about health and illness
(e.g., difficulty perceiving the benefits of DMTs on infre-
quently occurring relapses or disability progression),
high treatment costs and provider co-pays, limited access
to MS specialists and specialized treatment centers, and
restricted formularies.35 The self-assessments and patient
feedback were intended to motivate patients to learn
ways to surmount adherence obstacles. Informing provi-
ders about their patient’s adherence behaviors through
the summary page may help providers address patient’s
adherence challenges (many DMT nonadherent patients
do not tell their provider)55 and help them select DMTs
to which patients can more easily adhere. MS-
SUPPORT helped people understand the importance of
adherence and improved adherence expectations, which
is strongly associated with actual adherence.56 However,
actual adherence was not assessed.
This study builds upon a growing body of educational
tools for MS. These include a decision aid for managing
MS relapse,57,58 a booklet for women with MS consider-
ing motherhood,59 an information aid for newly diag-
nosed patients,60 a DMT booklet,58,61 and an interactive
tool that compares DMTs.62 MS-SUPPORT offers the
additional functionality of connecting patients to their
providers to improve patient—provider communication,
SDM, and adherence to treatment.
By helping patients understand their own goals and val-
ues and share them with their provider, MS-SUPPORT
may help providers comply with the American Academy
of Neurology’s recommendation that providers assess
patient preferences for DMTs.2 Combining preference
assessment with the other key elements of SDM should
enhance the effectiveness of this recommendation in
improving care.63 The other SDM elements include the
following: 1) informing patients when they need to be
involved in making a decision; 2) explaining why their pre-
ferences matter; 3) assessing patients’ desired level of invol-
vement in decision making; 4) helping interested patients
be more involved in decision making; and 5) assuring
patients of their provider’s support for their decision.
SDM tools such as MS-SUPPORT can help with most of
these elements, but only providers can demonstrate their
support for patients to participate in SDM. Providers thus
play an important role in either encouraging or impeding
patient involvement.64 Training providers in SDM and
providing SDM tools that can be used in clinical practice
should help providers create opportunities for patients to
discuss their needs and preferences and engage in partner-
ship building.44
Our pilot testing has many limitations that diminish
internal and external validity, notably small sample size
and lack of a control group. We relied on self-report,
which may have led to a tendency for more favorable
responses. Including only patients with an upcoming
appointment may have resulted in selecting patients with
more active disease. Many participants were relatively
well-educated, though less-educated people and people
with lower health literacy were included. Lower educa-
tional levels may prevent understanding of health infor-
mation and compromise participation in SDM,65 but
does not necessarily predict response to tools designed to
overcome literacy barriers.66 We did not confirm a diag-
nosis of MS but our referral sources made incorrect diag-
noses unlikely. Participating providers likely represented
higher performing providers who were willing to engage
in SDM, which could bias their responses. Our pilot test-
ing was not designed to establish the impact of the tool
but rather to improve the tool and guide future evalua-
tion in a larger and more diverse sample.
The positive response from both patients and health
care providers to the tool during beta testing establishes
the feasibility of the SDM intervention and procedures
for dissemination and clinical integration in real-life con-
ditions. The process of developing the MS-SUPPORT
tool can be applied to developing decision tools for other
health conditions.
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